sertralin mylan 100mg potahovaná tableta
viatris limited, dublin array - 13950 sertralin-hydrochlorid - potahovaná tableta - 100mg - sertralin
sertralin mylan 50mg potahovaná tableta
viatris limited, dublin array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
sertralin vipharm 100mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13950 sertralin-hydrochlorid - potahovaná tableta - 100mg - sertralin
sertralin vipharm 50mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
sertralin zentiva 25mg potahovaná tableta
zentiva, k.s., praha array - 13950 sertralin-hydrochlorid - potahovaná tableta - 25mg - sertralin
setaloft 100mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13950 sertralin-hydrochlorid - potahovaná tableta - 100mg - sertralin
setaloft 50mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
stimuloton 50mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
sublana 10mg/ml koncentrát pro perorální roztok
g.l. pharma gmbh, lannach array - 1786 methadon-hydrochlorid - koncentrát pro perorální roztok - 10mg/ml - methadon
nordimet
nordic group b.v. - metotrexát - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastická činidla - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.